http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114014911-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e7edc2841170dcdc290b9c6a21bf986f |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-04 |
| filingDate | 2021-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5c7bd40f25df81f86f440384ad34d548 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_578b5cd5c555ed0ecf5afd72feb386a7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5866ba552a71ced3b9c40aa8586a7e9f |
| publicationDate | 2022-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114014911-A |
| titleOfInvention | Preparation of anticancer lipopeptide and application thereof in antitumor treatment |
| abstract | The invention relates to an anticancer lipopeptide C 8 H 15 The preparation of O-Asp-Ser-Asp-Val-Trp-Trp-Gly-Gly-Arg-Arg-Leu-Leu-Arg-Arg-Arg-Leu and the application thereof in the anti-tumor treatment, belonging to the field of biological medicine. The anticancer lipopeptides are prepared based on key biological features of membrane-cleavable peptides (positive charge, alpha-helical structure and amphiphilicity). The invention provides a solid-phase synthesis method of the anticancer lipopeptide. The anticancer lipopeptide applianceHas the characteristics of small hydrophobic moment, low hemolytic activity and good serum stability, can effectively make up the defect of high hemolytic toxicity of most anticancer peptides, and solves the problem of poor in-vivo stability of peptide drugs. In vitro anticancer experiments and in vivo antitumor experiments prove that the anticancer lipopeptide has good antitumor effect and good application prospect. |
| priorityDate | 2021-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 107.